We are live on ! Find out more
SM

Sabby Management Portfolio holdings

AUM $45.1M
1-Year Est. Return 74.25%
This Fund
S&P 500
This Quarter Est. Return
+12.46%
1 Year Est. Return
-74.25%
3 Year Est. Return
-95.86%
5 Year Est. Return
-99.36%
10 Year Est. Return
-99.46%
AUM
$670M
AUM Growth
+$172M
Cap. Flow
+$37.5M
Cap. Flow %
5.59%
Top 10 Hldgs %
63.01%
Holding
164
New
62
Increased
39
Reduced
20
Closed
34

Top Buys

Rank Stock Value
1
AZN icon
AstraZeneca
AZN
+$6.49M
2
CNVS icon
Cineverse
CNVS
+$6.05M
3
SHIP icon
Seanergy Maritime Holdings
SHIP
+$5.68M
4
RMTI icon
Rockwell Medical
RMTI
+$5.66M
5
SRNE
Sorrento Therapeutics, Inc.
SRNE
+$5.55M

Top Sells

Rank Stock Value
1
BIIB icon
Biogen
BIIB
+$16.6M
2
XLV icon
State Street Health Care Select Sector SPDR ETF
XLV
+$10.7M
3
XERS icon
Xeris Biopharma Holdings
XERS
+$2.89M
4
PLLL
Piedmont Lithium Limited American Depositary Receipts
PLLL
+$2.88M
5
ALNA
Allena Pharmaceuticals
ALNA
+$2.42M

Sector Composition

Rank Sector Weight
1 Healthcare 12.1%
2 Technology 0.73%
3 Industrials 0.54%
4 Communication Services 0.41%
5 Consumer Staples 0.11%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
LSTA icon
101
Lisata Therapeutics
LSTA
$9.93M
$173K 0.03%
+6,400
New +$202K
ATXS
102
CALL
DELISTED
Astria Therapeutics
ATXS
$171K 0.03%
46
+29
+171% +$1.15K
GOVXW
103
DELISTED
GeoVax Labs Warrants
GOVXW
$169K 0.03%
+191,657
New +$162K
ATNM icon
104
PUT
Actinium Pharmaceuticals
ATNM
$26.3M
$159K 0.02%
+164
New +$1.81K
AVEO
105
DELISTED
AVEO Pharmaceuticals, Inc.
AVEO
$155K 0.02%
26,039
-61,280
-70% -$303K
EMAN
106
PUT
DELISTED
eMagin Corporation
EMAN
$149K 0.02%
+1,172
New +$1.4K
NMTR
107
PUT
DELISTED
9 Meters Biopharma
NMTR
$145K 0.02%
+89
New +$1.08K
NBRV
108
DELISTED
Nabriva Therapeutics plc Ordinary Shares Ireland
NBRV
$143K 0.02%
+1,072
New +$179K
CRMD icon
109
CALL
CorMedix
CRMD
$564M
$142K 0.02%
+236
New +$1.19K
LPCN icon
110
CALL
Lipocine
LPCN
$17.1M
$133K 0.02%
+55
New +$1.46K
CRIS icon
111
CALL
Curis
CRIS
$9.71M
$132K 0.02%
+3
New +$1.42K
DMK
112
PUT
DELISTED
DMK Pharmaceuticals Corporation Common Stock
DMK
$122K 0.02%
+22
New +$1.3K
BXRX
113
PUT
DELISTED
Baudax Bio, Inc. Common Stock
BXRX
– –
0
– –
EVOK
114
DELISTED
Evoke Pharma
EVOK
$105K 0.02%
+155
New +$98.9K
LMFA
115
DELISTED
LM Funding America
LMFA
$97K 0.01%
196
+163
+494% +$126K
MDGSW
116
DELISTED
Medigus Ltd. Series C Warrant
MDGSW
$93K 0.01%
544,940
-40,919
-7% -$8.44K
CTXR icon
117
Citius Pharmaceuticals
CTXR
$15.6M
$92K 0.01%
+3,548
New +$100K
BIOL
118
DELISTED
Biolase, Inc.
BIOL
$92K 0.01%
+133
New +$125K
EFOI icon
119
PUT
Energy Focus
EFOI
$18M
$82K 0.01%
17
– –
NSPR icon
120
InspireMD
NSPR
$31.4M
$77K 0.01%
16,260
+13,040
+405% +$82.7K
BNTC icon
121
Benitec Biopharma
BNTC
$414M
$75K 0.01%
698
– –
CRMD icon
122
PUT
CorMedix
CRMD
$564M
$66K 0.01%
+109
New +$547
ZOM
123
DELISTED
Zomedica Corp.
ZOM
$52K 0.01%
+470,548
New +$64.8K
NBRV
124
PUT
DELISTED
Nabriva Therapeutics plc Ordinary Shares Ireland
NBRV
$51K 0.01%
+4
New +$669
RDGT
125
Ridgetech Inc
RDGT
$692K
$48K 0.01%
1
– –
3 4
5
6 7

Similar funds

CG
Circumference Group Little Rock, Arkansas $44.6M AUM 5.21% 1-Year Est. Return
OC
Optimas Capital Central, Hong Kong $44.5M AUM 24.43% 1-Year Est. Return
ICCON
Investment Counsel Company of Nevada Las Vegas, Nevada $44.5M AUM 21.97% 1-Year Est. Return
PCM
Prentice Capital Management Greenwich, Connecticut $45.7M AUM 2.65% 1-Year Est. Return
CAS
CTC Alternative Strategies Chicago, Illinois $44M AUM 43.15% 1-Year Est. Return
CM
Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return
MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
AB
Aozora Bank Tokyo, Japan $43.6M AUM 1.15% 1-Year Est. Return

Sabby Management's Q3 2020 Portfolio in Review

As of Q3 2020, Sabby Management held 164 positions worth $670M, up 34% from $498M the previous quarter. Its ten largest holdings account for 63% of the portfolio.

Sabby Management deployed $37.5M of net new capital in Q3 2020, opening 62 new positions and adding to 39 existing holdings. Its largest new stake was Cineverse: 243,797 shares worth $2.75M.

By sector, the portfolio is most concentrated in Healthcare at 12% of assets, up from 11% a quarter earlier, followed by Technology and Industrials.

On the sell side, the largest reduction was Biogen, an estimated $16.6M trimmed.

  • Sabby Management's largest Q3 2020 buy was Cineverse: 243,797 shares worth $2.75M.
  • Sabby Management added most to AstraZeneca in Q3 2020, an estimated $6.49M increase.
  • Sabby Management's biggest Q3 2020 reduction was Biogen, cutting an estimated $16.6M.
  • Sabby Management fully exited Xeris Biopharma Holdings in Q3 2020, selling an estimated $2.89M.
  • Sabby Management's ten largest holdings make up 63% of its $670M portfolio in Q3 2020.
  • Sabby Management opened 62 new positions and closed 34 in Q3 2020.
  • Sabby Management's portfolio value rose 34% quarter-over-quarter to $670M.

Based on Sabby Management's 13F filing for Q3 2020, filed 16 Nov 2020.